Developer docs
API playgroundTry for free, no card

Search company profiles

NanoInnovations

Full company profile

uuid0002uce

Namestring
NanoInnovations
Legal namestring
NanoInnovations
Company typeenum
Private
Founded yearint
2014
Descriptiontext

NanoInnovations is a privately held, research and development-stage company founded in 2014 by Dr. Huma Jafry and headquartered in Sugar Land, Texas. The company is building a smart nanosensor platform combined with Machine Learning algorithms for healthcare analytics, focused on non-invasive analysis of bio-fluids such as sweat and saliva to generate patient-specific diagnostic and prognostic outputs. Active and planned use cases include COVID-19 severity prediction, diabetes monitoring, and heart failure detection.

The company's core offering is a single Smart Nanosensor Platform that gathers multivariate data from bio-fluids and applies AI/ML algorithms for real-time analysis. The underlying technology originated from the founder's Ph.D. and postdoctoral work in Nanomaterials Chemistry at Rice University, with early-stage development catalyzed by participation in the Wendy Schmidt Ocean Health xPrize Competition. As of December 2020, NanoInnovations is collaborating with the University of Texas Health Science in Houston on an NSF-funded project to develop AI-based algorithms for predicting COVID-19 clinical outcomes using salivary analytics.

NanoInnovations operates with 1-10 employees and has no disclosed commercial revenue. Its primary disclosed funding is a $247,239 National Science Foundation Small Business Technology Transfer (STTR) Phase I grant awarded in December 2020. The company is pre-commercial, monetizing through research grants and academic partnerships rather than direct enterprise sales, and no institutional venture capital or private equity backing is disclosed in the available sources.

Short descriptiontext

NanoInnovations is an R&D-stage company developing a smart nanosensor platform with Machine Learning algorithms for non-invasive healthcare diagnostics via bio-fluid analysis, targeting COVID-19 severity prediction, diabetes, and heart failure monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSugar Land, United States
HQ citystring
Sugar Land
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanosensor diagnostics, healthcare analytics platform, biofluid sensor technology, predictive health monitoring, AI medical diagnostics
Industry3 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in Nanotechnology541713
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Medical Diagnostics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Research Grants
TypeSubscription Recurring
Description

The company currently operates primarily through research grants, including NSF STTR funding for COVID-19 diagnostic development. This represents early-stage funding for R&D rather than commercial revenue.

nanoinnovations-health.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

NanoInnovations develops a smart nanosensor platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs. The technology is applied to healthcare analytics use cases including diabetes monitoring, heart failure detection, and COVID-19 severity prediction. The company is currently in the research and development stage, validating its platform through partnerships with universities and healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Accurate prediction of COVID-19 illness severity at initial diagnosis
Product overview1 text field

NanoInnovations offers a single unified product: the Smart Nanosensor Platform. This platform combines smart nanosensor technology with Machine Learning algorithms to collect multivariate data from bio-fluids (sweat and saliva) and generate real-time diagnostic and prognostic outputs for healthcare analytics. The platform has been applied to diabetes monitoring, heart failure detection, and COVID-19 severity prediction through AI-based algorithms.

Product and service2 records
1Smart Nanosensor Platform
CategoryMedical Diagnostics
Description

A versatile nanosensor-based platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs for healthcare applications including diabetes monitoring, heart failure detection, and infectious disease management. Targeted at hospitals, healthcare systems, and research institutions.

2AI-Based COVID-19 Severity Prediction Algorithm
CategoryMedical Diagnostics
Description

An AI-based algorithm that combines nanosensors with salivary analytics to predict clinical outcomes in COVID-19 patients, designed to predict illness severity at initial diagnosis and enable efficient hospital resource allocation. Targeted at hospitals and clinical research institutions.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-17
Description

NanoInnovations is collaborating with the University of Texas Health Science in Houston for a NSF-funded research project to develop AI-based algorithms using nanosensors and salivary analytics for predicting clinical outcomes in COVID-19 patients. This partnership enables the company to access clinical research capabilities and academic expertise for technology validation and development.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Market-leading CGM manufacturer with FDA-cleared continuous glucose sensors, representing the established standard NanoInnovations would need to displace for diabetes monitoring.

TypeEmerging player
Description

Breath-based diagnostics platform leveraging proprietary sensor technology plus analytics for disease detection — analogous approach of using novel sensor chemistry with AI to deliver clinical outputs.

TypeBroad incumbent
Description

Dominant incumbent in continuous glucose monitoring via Freestyle Libre, addressing the same diabetes-monitoring use case NanoInnovations targets with its bio-fluid nanosensors.

TypeEmerging player
Description

Developer of an implantable long-term continuous glucose sensor; comparable as a smaller, sensor-focused diagnostics company pursuing non-traditional bio-fluid monitoring.

5Cardea Bio
TypeDirect peer
Description

Develops graphene-biosensor chips for molecular and health analytics, sharing NanoInnovations' core concept of pairing novel nano-scale biosensors with AI/ML data interpretation for diagnostics.

TypeEmerging player
Description

Developer of a single-molecule protein sequencing platform with embedded AI analytics; comparable as an instrument-plus-AI diagnostics company in early commercial stages.

TypeDirect peer
Description

Builds injectable and wearable biosensors for continuous monitoring of bio-fluids (interstitial fluid, sweat), directly comparable to NanoInnovations' nanosensor platform for non-invasive chronic disease monitoring.

TypeBroad incumbent
Description

Provides multiplexed diagnostics and life-science research tools, relevant as a broader platform vendor in advanced diagnostics with both research and clinical applications.

9Cue Health
TypeEmerging player
Description

Molecular diagnostics platform with connected at-home testing (notably COVID-19), directly relevant as a comparator in AI-enabled diagnostics from non-traditional samples.

TypeBroad incumbent
Description

Major medical device incumbent offering continuous glucose monitoring and broader diagnostic products; comparable as an established competitor that NanoInnovations would need to partner with or displace.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NanoInnovations

Medical Diagnosticsnanoinnovations-health.com

NanoInnovations is an R&D-stage company developing a smart nanosensor platform with Machine Learning algorithms for non-invasive healthcare diagnostics via bio-fluid analysis, targeting COVID-19 severity prediction, diabetes, and heart failure monitoring.

What NanoInnovations does

NanoInnovations is a privately held, research and development-stage company founded in 2014 by Dr. Huma Jafry and headquartered in Sugar Land, Texas. The company is building a smart nanosensor platform combined with Machine Learning algorithms for healthcare analytics, focused on non-invasive analysis of bio-fluids such as sweat and saliva to generate patient-specific diagnostic and prognostic outputs. Active and planned use cases include COVID-19 severity prediction, diabetes monitoring, and heart failure detection.

The company's core offering is a single Smart Nanosensor Platform that gathers multivariate data from bio-fluids and applies AI/ML algorithms for real-time analysis. The underlying technology originated from the founder's Ph.D. and postdoctoral work in Nanomaterials Chemistry at Rice University, with early-stage development catalyzed by participation in the Wendy Schmidt Ocean Health xPrize Competition. As of December 2020, NanoInnovations is collaborating with the University of Texas Health Science in Houston on an NSF-funded project to develop AI-based algorithms for predicting COVID-19 clinical outcomes using salivary analytics.

NanoInnovations operates with 1-10 employees and has no disclosed commercial revenue. Its primary disclosed funding is a $247,239 National Science Foundation Small Business Technology Transfer (STTR) Phase I grant awarded in December 2020. The company is pre-commercial, monetizing through research grants and academic partnerships rather than direct enterprise sales, and no institutional venture capital or private equity backing is disclosed in the available sources.

NanoInnovations firmographics

Firmographics
Name
NanoInnovations
Legal name
NanoInnovations
Website
https://nanoinnovations-health.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
NanoInnovations is an R&D-stage company developing a smart nanosensor platform with Machine Learning algorithms for non-invasive healthcare diagnostics via bio-fluid analysis, targeting COVID-19 severity prediction, diabetes, and heart failure monitoring.
Ownership category
akta.pro rank

NanoInnovations industry classification

Industry
Product category
Medical Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in Nanotechnology (541713)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Nanosensor diagnostics
  • Healthcare analytics platform
  • Biofluid sensor technology
  • Predictive health monitoring
  • AI medical diagnostics

Where NanoInnovations is headquartered

Location

Headquarters

HQ city
Sugar Land
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NanoInnovations business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Research Grants: The company currently operates primarily through research grants, including NSF STTR funding for COVID-19 diagnostic development. This represents early-stage funding for R&D rather than commercial revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NanoInnovations product offering

Product offering

Core offering

NanoInnovations develops a smart nanosensor platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs. The technology is applied to healthcare analytics use cases including diabetes monitoring, heart failure detection, and COVID-19 severity prediction. The company is currently in the research and development stage, validating its platform through partnerships with universities and healthcare providers.

Product overview

NanoInnovations offers a single unified product: the Smart Nanosensor Platform. This platform combines smart nanosensor technology with Machine Learning algorithms to collect multivariate data from bio-fluids (sweat and saliva) and generate real-time diagnostic and prognostic outputs for healthcare analytics. The platform has been applied to diabetes monitoring, heart failure detection, and COVID-19 severity prediction through AI-based algorithms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Smart Nanosensor Platform A versatile nanosensor-based platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs for healthcare applications including diabetes monitoring, heart failure detection, and infectious disease management. Targeted at hospitals, healthcare systems, and research institutions.
  • AI-Based COVID-19 Severity Prediction Algorithm An AI-based algorithm that combines nanosensors with salivary analytics to predict clinical outcomes in COVID-19 patients, designed to predict illness severity at initial diagnosis and enable efficient hospital resource allocation. Targeted at hospitals and clinical research institutions.

Quantifiable outcome

  • Accurate prediction of COVID-19 illness severity at initial diagnosis

Companies that use NanoInnovations

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

NanoInnovations technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

NanoInnovations partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of Texas Health Science in HoustoncoreStrategic or Co-development Partner · 17 December 2020NanoInnovations is collaborating with the University of Texas Health Science in Houston for a NSF-funded research project to develop AI-based algorithms using nanosensors and salivary analytics for predicting clinical outcomes in COVID-19 patients. This partnership enables the company to access clinical research capabilities and academic expertise for technology validation and development.

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

NanoInnovations competitors and assessment

Company assessment

Broad incumbents

  • Dexcom: Market-leading CGM manufacturer with FDA-cleared continuous glucose sensors, representing the established standard NanoInnovations would need to displace for diabetes monitoring.
  • Abbott (Diabetes Care / Freestyle Libre): Dominant incumbent in continuous glucose monitoring via Freestyle Libre, addressing the same diabetes-monitoring use case NanoInnovations targets with its bio-fluid nanosensors.
  • Nanostring Technologies: Provides multiplexed diagnostics and life-science research tools, relevant as a broader platform vendor in advanced diagnostics with both research and clinical applications.
  • Medtronic (Diabetes / Diagnostics): Major medical device incumbent offering continuous glucose monitoring and broader diagnostic products; comparable as an established competitor that NanoInnovations would need to partner with or displace.

Emerging players

  • Owlstone Medical: Breath-based diagnostics platform leveraging proprietary sensor technology plus analytics for disease detection — analogous approach of using novel sensor chemistry with AI to deliver clinical outputs.
  • Senseonics (Eversense): Developer of an implantable long-term continuous glucose sensor; comparable as a smaller, sensor-focused diagnostics company pursuing non-traditional bio-fluid monitoring.
  • Quantum-Si: Developer of a single-molecule protein sequencing platform with embedded AI analytics; comparable as an instrument-plus-AI diagnostics company in early commercial stages.
  • Cue Health: Molecular diagnostics platform with connected at-home testing (notably COVID-19), directly relevant as a comparator in AI-enabled diagnostics from non-traditional samples.

Direct peers

  • Cardea Bio: Develops graphene-biosensor chips for molecular and health analytics, sharing NanoInnovations' core concept of pairing novel nano-scale biosensors with AI/ML data interpretation for diagnostics.
  • Profusa: Builds injectable and wearable biosensors for continuous monitoring of bio-fluids (interstitial fluid, sweat), directly comparable to NanoInnovations' nanosensor platform for non-invasive chronic disease monitoring.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

NanoInnovations social profiles

Digital presence

NanoInnovations financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NanoInnovations leadership team

Management profile

Number of profiles

Profiles4 records

NanoInnovations funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NanoInnovations M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoInnovations

What does NanoInnovations do?

NanoInnovations develops a smart nanosensor platform that gathers multivariate data from bio-fluids such as sweat and saliva, which is analyzed in real-time with AI/ML algorithms to generate patient-specific diagnostic and prognostic outputs. The technology is applied to healthcare analytics use cases including diabetes monitoring, heart failure detection, and COVID-19 severity prediction. The company is currently in the research and development stage, validating its platform through partnerships with universities and healthcare providers.

Is NanoInnovations a public or private company?

NanoInnovations is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NanoInnovations founded?

NanoInnovations was founded in 2014. It employs 1 to 10 people.

Where is NanoInnovations based?

NanoInnovations is headquartered in Sugar Land, United States, in the North America region.

How does NanoInnovations make money?

One revenue line is on record: research Grants.

Who are NanoInnovations's main competitors?

Broad incumbents on record are Dexcom, Abbott (Diabetes Care / Freestyle Libre), Nanostring Technologies and Medtronic (Diabetes / Diagnostics). Emerging players are Owlstone Medical, Senseonics (Eversense), Quantum-Si and Cue Health. Direct peers are Cardea Bio and Profusa.

Does NanoInnovations have an API?

No public API is recorded for NanoInnovations.

What industry is NanoInnovations in?

NanoInnovations's product category is Medical Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales